Court Backs Dr. Reddy's Semaglutide Exports, Igniting Global Generic Race

A significant court ruling backing Dr. Reddy's Laboratories' ability to export semaglutide marks a major shift in the pharmaceutical landscape. The decision challenges originator exclusivity and paves the way for a more competitive market for the blockbuster drug.

Semaglutide Export Verdict

On March 9, 2026, a Delhi High Court division bench rejected Novo Nordisk's attempt to block Dr. Reddy's Laboratories from producing and exporting semaglutide. The ruling confirms Dr. Reddy's right to manufacture the drug's active ingredient (API) for countries where Novo Nordisk's patents are not active, upholding a prior December 2025 order. This decision allows Dr. Reddy's to pursue international markets ahead of Novo Nordisk's Indian patent expiry for semaglutide on March 20, 2026. The court found Dr. Reddy's presented a credible challenge to Novo Nordisk's patent claims, citing concerns about 'evergreening' and double patenting strategies by the Danish company. Dr. Reddy's, which has invested heavily in domestic manufacturing, saw its shares trade around ₹1,285, with the company's market capitalization at approximately ₹1,07,252 crore.

India's Generics Poised to Enter Global Market

This legal win for Dr. Reddy's empowers India's strong generic pharmaceutical sector. With semaglutide patents expiring in major markets like India, China, Canada, and Brazil from March 2026, a multi-billion-dollar revenue opportunity is emerging. Analysts forecast significant price drops for semaglutide treatments, possibly by 30-75%, as generics enter. This will make the vital drugs more accessible to a wider patient base. Companies like Sun Pharma, Lupin, Zydus Lifesciences, and Natco Pharma are set to launch their own semaglutide generics. This intensifies competition for blockbuster drugs like Ozempic and Wegovy, which collectively generated over $26 billion globally in 2024.

Novo Nordisk Plans New Brand Launch in India

Despite this setback, Novo Nordisk, with a market cap around $167 billion and a P/E ratio of about 10.64, is continuing its strategic moves. The company plans to launch its new semaglutide brand, Extensior, in India to strengthen its market position before generic competition becomes widespread. This move shows Novo Nordisk's focus on maximizing revenue from its semaglutide drugs as patent expiries approach. Analyst sentiment for Novo Nordisk is mixed, with a consensus 'Hold' rating from many brokerages. Goldman Sachs recently reiterated a neutral rating and cut its price target, reflecting concerns about competition and potential margin squeeze.

Patent Strategy Faces Scrutiny

The court's skepticism about Novo Nordisk's patent strategy, particularly regarding 'evergreening' and secondary patents on minor variations, raises questions about the company's long-term market exclusivity tactics. Although Novo Nordisk holds a strong market position, its aggressive patent enforcement has faced global scrutiny and legal challenges. Intense price wars are likely, especially as competitors like Eli Lilly advance their own GLP-1 therapies, such as tirzepatide. For Dr. Reddy's, with a P/E ratio around 19.75 offering a potentially attractive valuation, the company must navigate rapid market shifts and potential originator strategies. Dr. Reddy's recent Q4 2025 net profit decline of 89.3% year-over-year highlights the sector's inherent volatility and challenges.

Global Access and Affordability Take Center Stage

As semaglutide patents expire, the focus shifts to increased global access and affordability. Industry insiders anticipate a flood of brands as over two dozen Indian firms prepare to launch generic versions. The cost of treatment is expected to drop dramatically, potentially benefiting millions worldwide suffering from diabetes and obesity. While Novo Nordisk aims to maintain its premium segment, the market is leaning towards generic-led accessibility. This is supported by a consensus 'Hold' rating for Dr. Reddy's, with an average target price around ₹1,310. The unfolding patent expirations and subsequent generic entries will redefine the multibillion-dollar GLP-1 market for years to come.